OssDsign AB
STO:OSSD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6
10.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OssDsign AB
Gross Profit
OssDsign AB
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OssDsign AB
STO:OSSD
|
Gross Profit
kr83.6m
|
CAGR 3-Years
74%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Gross Profit
kr558.5m
|
CAGR 3-Years
51%
|
CAGR 5-Years
29%
|
CAGR 10-Years
25%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Gross Profit
kr11.7m
|
CAGR 3-Years
125%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Gross Profit
kr61.3m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Gross Profit
€165.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Gross Profit
kr9.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
OssDsign AB
Glance View
OssDsign AB is a holding company, which designs, manufactures, and sells implants and material technology for bone regeneration. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2019-05-24. The company aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The firm uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The firm's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
See Also
What is OssDsign AB's Gross Profit?
Gross Profit
83.6m
SEK
Based on the financial report for Dec 31, 2023, OssDsign AB's Gross Profit amounts to 83.6m SEK.
What is OssDsign AB's Gross Profit growth rate?
Gross Profit CAGR 5Y
41%
Over the last year, the Gross Profit growth was 139%. The average annual Gross Profit growth rates for OssDsign AB have been 74% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
